Published 02-06-18
Issued by Novo Nordisk
Novo Nordisk, a global healthcare company specialising in diabetes, obesity and other serious chronic diseases, published its Annual Report 2017 online today at novonordisk.com/annualreport. It is the company's fourteenth integrated annual report accounting for the company's financial, social and environmental performance.
Novo Nordisk, a global healthcare company specialising in diabetes, obesity and other serious chronic diseases, published its Annual Report 2017 online today at novonordisk.com/annualreport. It is the company's fourteenth integrated annual report accounting for the company's financial, social and environmental performance.
Since 2004, Novo Nordisk has published an integrated report to reflect the Novo Nordisk Triple Bottom Line business principle. The report includes financial, environmental and social statements for the year, as well as a management review. As a participant to the UN Global Compact, Novo Nordisk also submits a Communication on Progress report, detailing how company principles are translated into concrete actions with regards to human rights, labour, environment and anti-corruption.
“The actions we take will inevitably impact people, communities and the environment. That’s why we use the Triple Bottom Line principle to guide decisions and always strive to achieve a good balance between financial, social and environmental dimensions of performance. We want to maximise our positive impacts and minimise any adverse impacts of our business. This is what doing business responsibly means to us,” explains Lars Fruergaard Jørgensen, president and CEO.
The management review presents the company’s strategy and actions to be a sustainable business. Highlights are:
Pipeline progress
Financial performance
Social performance
Environmental performance
The full report can be downloaded as a PDF and will be available in print later this month.
Contacts:
Novo Nordisk Media Relations
Katrine Rud von Sperling
Novo Nordisk Investor Relations
Peter Hugreffe Ankersen
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.